AVTX Avalo Therapeutics Inc
Price (delayed)
$7.08
Market cap
$75.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.94
Enterprise value
-$59.01M
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of
Highlights
The EPS has soared by 93% YoY and by 57% from the previous quarter
The company's gross profit fell by 46% QoQ but it rose by 26% YoY
AVTX's revenue has shrunk by 77% YoY and by 46% QoQ
AVTX's net income is down by 11% YoY
Key stats
What are the main financial stats of AVTX
Market
Valuations
Earnings
Shares outstanding
10.67M
Market cap
$75.56M
Enterprise value
-$59.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.55
Price to sales (P/S)
166.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-133.8
Revenue
$441,000
Gross profit
$807,000
Operating income
-$68.51M
Net income
-$35.13M
EBIT
-$38.33M
EBITDA
-$38.16M
Free cash flow
-$49.06M
Per share
Balance sheet
Liquidity
EPS
-$7.94
EPS diluted
-$20.91
Free cash flow per share
-$4.72
Book value per share
$12.8
Revenue per share
$0.04
TBVPS
$13.49
Total assets
$150.73M
Total liabilities
$17.7M
Debt
$0
Equity
$133.03M
Working capital
$131.93M
Debt to equity
0
Current ratio
19.96
Quick ratio
19.42
Net debt/EBITDA
3.53
Margins
Efficiency
Dividend
EBITDA margin
-8,653.7%
Gross margin
183%
Net margin
-7,965.8%
Operating margin
-15,535.6%
Return on assets
-29.2%
Return on equity
-502.6%
Return on invested capital
N/A
Return on capital employed
-26.7%
Return on sales
-8,692.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVTX stock price
How has the Avalo Therapeutics stock price performed over time
Intraday
3.36%
1 week
-15.31%
1 month
-3.15%
1 year
-53.3%
YTD
-4.71%
QTD
-11.61%
Financial performance
How have Avalo Therapeutics's revenue and profit performed over time
Revenue
$441,000
Gross profit
$807,000
Operating income
-$68.51M
Net income
-$35.13M
Gross margin
183%
Net margin
-7,965.8%
AVTX's operating income has shrunk by 150% YoY and by 9% QoQ
AVTX's operating margin has dropped by 103% since the previous quarter
AVTX's revenue has shrunk by 77% YoY and by 46% QoQ
The company's gross profit fell by 46% QoQ but it rose by 26% YoY
Growth
What is Avalo Therapeutics's growth rate over time
Valuation
What is Avalo Therapeutics stock price valuation
P/E
N/A
P/B
0.55
P/S
166.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-133.8
The EPS has soared by 93% YoY and by 57% from the previous quarter
The P/S is 196% higher than the last 4 quarters average of 54.6
AVTX's revenue has shrunk by 77% YoY and by 46% QoQ
Efficiency
How efficient is Avalo Therapeutics business performance
Avalo Therapeutics's ROA has soared by 74% YoY
The ROE has soared by 65% year-on-year
Dividends
What is AVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVTX.
Financial health
How did Avalo Therapeutics financials performed over time
AVTX's total liabilities has dropped by 77% since the previous quarter but it is up by 29% year-on-year
AVTX's total assets has surged by 53% since the previous quarter
The debt is 100% smaller than the equity
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.